Valeant Pharmaceuticals International, Inc. (TSX: VRX) made a hostile offer to acquire Cephalon Inc. (NasdaqGS: CEPH) for $5.5 billion..
"Valeant Pharmaceuticals International, Inc. (TSX: VRX) made a hostile offer to acquire Cephalon Inc. (NasdaqGS: CEPH) for $5.5 billion in cash on March 18, 2011. Valeant Pharmaceuticals will acquire Cephalon for $73 per share in cash. The transaction is expected to be debt financed. Goldman Sachs & Co. is providing full amount of financing for the transaction. The transaction is subject to negotiation and execution of a definitive merger agreement and due diligence investigation. The transaction is not subject to financing contingency. The Valeant's Board of Directors has unanimously approved the transaction. Valeant would replace Cephalon's Board with its own nominees. The transaction is expected to be accretive immediately and longer term. Deutsche Bank Securities Inc. acted as financial advisor and Eileen Nugent and Neil Stronski of Skadden, Arps, S"
